New and emerging pharmacologic strategies in the management of chronic heart failure

Clinical Cardiology

Volumn 23, Issue 10, 2000, Pages 724-730

  Krum, H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Chronic heart failure; Endothelin 1; Natriuretic peptide; Tumor necrosis factor

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL ) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE; 2' AMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 4' ISOBUTYLBIPHENYL 2 SULFONAMIDE; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CANDESARTAN; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENRASENTAN; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; SB 247083; SITAXSENTAN; TAK 044; TARASENTAN; TEZOSENTAN; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; AGED; APOPTOSIS; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; VASCULAR ENDOTHELIUM;

EID: 0033802542     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960231008     Document Type: Review

References (56)

1. The evidence for β-blockers in heart failure
2. The effects of carvedilol on morbidity and mortality in patients with heart failure
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
4. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): A randomised trial
5. Cardiac myocyte necrosis induced by angiotensin II
6. Randomised trial of losartan versus captopril in patients over 65 with heart failure
7. Aldosterone and antialdosterone therapy in congestive heart failure
8. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
9. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
10. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
11. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction
12. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
13. Angiotensin II receptor antagonists for heart failure
14. Comparison of candesartan, enalapril, and their combination in congestive heart failure: The randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
15. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
16. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
17. Endothelin as a regulator of cardiovascular function in health and disease
18. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factors
19. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells: Receptor coupling to nitric oxide synthase
20. Plasma endothelin in chronic heart failure
21. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
22. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
23. Plasma endothelin correlate with the extent of pulmonary hypertension in patients with chronic congestive heart failure
24. Role of endothelin in the exercise intolerance of chronic heart failure
25. Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction
26. Evidence for endothelin-l-mediated vasoconstriction in severe chronic heart failure
27. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
28. Effect of oral mikinone on mortality in severe chronic heart failure
29. Effect of flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE study
30. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure
31. Xamoterol in severe heart failure
32. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
33. Multicenter, double-blind, placebo-controlled study of long-term endothelm blockade with bosentan in chronic heart failure: Results of the REACH-1 trial
34. Contribution of endogenous generation of endothelin-1 to basal vascular tone
35. Endothelins in the normal and diseased kidney
36. Role of endothelin in the increased vascular tone of patients with essential hypertension
37. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ET(A) receptor blockade in chronic heart failure patients treated with ACE inhibition
38. Therapeutic potential of endothelin-converting enzyme inhibitors
39. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
40. Increased concentrations of tumour necrosis factor in 'cachectic' patients with severe chronic heart failure
41. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure
42. Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium
43. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
44. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats
45. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α
46. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy
47. Basic mechanisms in congestive heart failure: Recognizing the role of proinflammatory cytokines
48. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy
49. Results of multidose Phase I trial with tumor necrosis factor receptor (p75) fusion protein (etanercept) in patients with heart failure
50. Natriuretic peptides
51. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial
52. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure
53. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption
54. Vasopeptidase inhibitor or angiotensin-converting enzyme inhibitor in heart failure? Results of the IMPRESS trial